Dupilumab suppresses type 2 inflammatory biomarkers across multiple atopic, allergic diseases.

Jennifer D HamiltonSivan HarelBrian N SwansonWilliam BrianZhen ChenMegan S RiceNikhil AminMarius ArdeleanuAllen RadinBrad ShumelMarcella RuddyNaimish PatelGianluca PirozziLeda MannentNeil M H Graham

Published in: Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology (2021)

Dupilumab reduced levels of type 2 biomarkers across clinical studies in patients with AD, asthma, CRSwNP and EoE.

Keyphrases

atopic dermatitis
chronic obstructive pulmonary disease
allergic rhinitis
signaling pathway
oxidative stress
lung function
cystic fibrosis